With 18,000 researchers, patient advocates, and other professionals in cancer and related fields in attendance, the AACR conference is the premier cancer research event where the latest and most exciting basic, translational, and clinical discoveries are presented.
Dr. Bakker’s talk focused on the following points:
Medical foundations like the Children’s Tumor Foundation are strategically investing to fill the gaps that hamper the acceleration of science from basic discovery to clinical benefit.
It’s beneficial that the National Cancer Institute assist in the creation of a complete characterization of benign tumors such as neurofibromas and schwannomas.
Since more and more malignant tumors are showing mutations in NF, the Children’s Tumor Foundation’s investment in creating quality compounds benefits the entire oncology field.
Within the cancer community, it is essential that collaboration driven by multidisciplinary teams takes place. The Children’s Tumor Foundation launched its Synodos initiative in this manner and positive results are already being seen.
For more information about Synodos, please click here.
For more information about the American Association for Cancer Research’s annual conference, please click here.
